Myriad Genetics expands Precise MRD cancer test to three tumor types
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- Americold to wind down Ahold Delhaize facilities, take $305M charge
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Did Google and Tesla just break AI trade’s bull case?
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
June 23, 2026 9:05 AM EDTPublication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD
SALT LAKE CITY, June 23, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces expanded availability of Precise MRD, broadening availability to patients undergoing treatment and surveillance for breast, colorectal and renal cancers. More than 6 million individuals are living with these cancers in... More
